Methadone: a review of its pharmacokinetic/pharmacodynamic properties.
about
Adverse Effects of Opioids on the Central Nervous Systems of Palliative Care PatientsThe pharmacokinetics of methadone in adolescents undergoing posterior spinal fusion.The effects of maternally administered methadone, buprenorphine and naltrexone on offspring: review of human and animal data.A high-throughput method for assessing chemical toxicity using a Caenorhabditis elegans reproduction assayExamining the role of mu opioid receptor endocytosis in the beneficial and side-effects of prolonged opioid use: from a symposium on new concepts in mu-opioid pharmacologyFatal methadone toxicity: potential role of CYP3A4 genetic polymorphism.Prescribing to drug misusers in practice--often effective, but rarely straightforward.There is no age limit for methadone: a retrospective cohort studyBuprenorphine, methadone, and morphine treatment during pregnancy: behavioral effects on the offspring in rats.Expansion of a PBPK model to predict disposition in pregnant women of drugs cleared via multiple CYP enzymes, including CYP2B6, CYP2C9 and CYP2C19Addiction, physical dependence, and tolerance: precise definitions to help clinicians evaluate and treat chronic pain patients.Gender differences in pharmacokinetics and pharmacodynamics of methadone substitution therapyMethadone reincarnated: novel clinical applications with related concerns.The effect of quinidine, used as a probe for the involvement of P-glycoprotein, on the intestinal absorption and pharmacodynamics of methadone.Methadone and metabolites in hair of methadone-assisted pregnant women and their infants.Interpretation of oral fluid tests for drugs of abuse.Interindividual variability of methadone response: impact of genetic polymorphism.Comparing methadone and buprenorphine maintenance with methadone-assisted withdrawal for the treatment of opioid dependence during pregnancy: maternal and neonatal outcomes.A systematic review and empirical analysis of the relation between dose and duration of drug action.Prenatal exposure to methadone and buprenorphine: a review of the potential effects on cognitive development.Resting EEG and ERPs findings in methadone-substituted opiate users: a review.Metabolomics of methadone: clinical and forensic toxicological implications and variability of dose response.Quantitative EEG and Low-Resolution Electromagnetic Tomography (LORETA) Imaging of Patients Undergoing Methadone Treatment for Opiate Addiction.Blockade of morphine-induced behavioral sensitization by a combination of amisulpride and RB101, comparison with classical opioid maintenance treatments.Population pharmacokinetics and pharmacokinetic-pharmacodynamic relationships of methadone in a sample of Iranian (mazandarani) opiate users undergoing methadone maintenance treatment.Differential involvement of P-glycoprotein (ABCB1) in permeability, tissue distribution, and antinociceptive activity of methadone, buprenorphine, and diprenorphine: in vitro and in vivo evaluation.Case report: quantification of methadone-induced respiratory depression using toxicokinetic/toxicodynamic relationships.Going beyond efficacy: strategies for cancer pain management.Effect of raltegravir on the pharmacokinetics of methadone.Very-high-dose methadone with minimal toxicity and inadequate pain control in a hospice patient with cancer.An ad libitum schedule for conversion of morphine to methadone in advanced cancer patients: an open uncontrolled prospective study in a Chinese population.Determination of the unbound fraction of R- and S-methadone in human brain.Executive function in preschool children prenatally exposed to methadone or buprenorphine.The Effect of CYP2B6, CYP2D6, and CYP3A4 Alleles on Methadone Binding: A Molecular Docking Study
P2860
Q29029910-B2E06E73-CCC0-4119-8D48-A98CB4B4E203Q30456107-9DC7DB79-0E25-4B81-B75C-5E3B8CB09671Q30490602-E8F3A778-E5C1-41E8-8366-BA9E53921471Q33857233-D41CC9DF-E60B-4DCB-AA5B-3585B3C474C2Q34472770-6BEDC98B-6F42-40C7-997D-2AB25E53843EQ34500741-74CE80E8-2080-4B74-AEB0-796C0AAEDDA0Q34749114-2851BB3C-3758-4196-8DD7-EB559019597AQ35053957-9CAD301D-44A1-4D28-85BF-5914D7BECFE7Q35174033-DA191C82-50DA-4013-896A-46284027A4E5Q35211432-60AB8BD5-E51C-4D25-84EC-8F2C725D51A7Q35593793-E008D662-33B4-4472-95FD-19EAC9BF8472Q35698405-A631B860-B18E-4D3C-99A9-34B474F8A77AQ35751695-18EFBDCA-2DDC-4145-87F5-8EB2FDB8BCEBQ35826102-50E1A9BC-6566-4D23-9CC5-9E5D7D9BD64FQ36036257-6386C7E9-A770-4821-9559-DACE398EB528Q36748917-FAA8EDEA-FAEE-4AC4-9BE7-734D7745FC26Q37142009-6AAA8F61-4C87-44B7-8006-EB7362C346E6Q37467788-9296E50F-F11F-47F0-9A64-BE4BD4240F6BQ37606934-8D36829A-E398-42B1-8978-0D522D85FA15Q37863594-BD596286-1107-4F73-9B58-34169B4AFE8CQ38430425-1C5A6680-6768-44DA-A9DA-47506F6710CBQ38870014-7AE168BB-77CC-4275-B92C-4CCA3EC2AAB1Q40909210-28F67730-1502-4C50-A0F9-3238D5F679A7Q41556993-55E02D07-BC39-4C9A-8E02-A704B5FD410AQ41990976-0EB9F4F4-67AF-47EE-87C4-AE9F91BE05BBQ42101445-C9C74784-1D4D-4BFC-8B19-23C7B7BC6D7CQ42861755-DEE5B524-D14B-48B8-88FC-8536556356FDQ42976344-1966E8D2-2CB3-4C93-92D6-E733C10FD784Q43155085-48A3D3F4-FF12-44FE-8128-F30855663DD5Q44012678-21DC1D7D-CDA0-490C-87ED-D969AC6433B9Q44407817-6CDD6A58-A6CA-4040-B178-88C21F032ED9Q48604671-6DF1F625-4404-4E25-B6EF-060CCF9551A4Q50626128-49BDBE2C-DDB4-4D82-AADC-8FF430922FB7Q59009311-A0785616-E6B4-4F80-9891-1CE585B5C5F0
P2860
Methadone: a review of its pharmacokinetic/pharmacodynamic properties.
description
1999 nî lūn-bûn
@nan
1999 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
name
Methadone: a review of its pharmacokinetic/pharmacodynamic properties.
@ast
Methadone: a review of its pharmacokinetic/pharmacodynamic properties.
@en
type
label
Methadone: a review of its pharmacokinetic/pharmacodynamic properties.
@ast
Methadone: a review of its pharmacokinetic/pharmacodynamic properties.
@en
prefLabel
Methadone: a review of its pharmacokinetic/pharmacodynamic properties.
@ast
Methadone: a review of its pharmacokinetic/pharmacodynamic properties.
@en
P1476
Methadone: a review of its pharmacokinetic/pharmacodynamic properties
@en
P2093
Garrido MJ
Trocóniz IF
P356
10.1016/S1056-8719(00)00043-5
P577
1999-10-01T00:00:00Z